The Global Health Body Issues Alert Over Critical Lack of Obesity Jabs

Under a tenth of people who could benefit from obesity jabs including Wegovy can access them, caution the WHO as it releases its initial guidance on the therapies.

With over a billion individuals worldwide currently obese, it is calling for increased and just access to GLP-1 medication.

According to projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"Our latest guidelines recognises that excess weight is a lifelong illness that can be managed with holistic and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are significant hurdles to widespread availability to the jabs that can assist patients in reducing considerable body mass, notes the agency.

Skinny Jab Scarcity

Even under the present most favorable outlook, the manufacturing of such drugs would only suffice for approximately 100 million people – fewer than 10% of those who need them, per the health organization.

The advice urges countries and companies to widen access, through approaches including voluntary licensing.

Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.

The Way Obesity Injections Work

These medications imitate a natural hormone to slow digestion, reduce hunger and increase feelings of fullness so individuals eat less.

People typically begin shedding pounds in the initial weeks of beginning the weekly injections.

Evidence suggests patients may see weight return after a year of discontinuing the medication, because their normal hunger come back.

To be above a healthy weight increases your risk for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.

Obesity impacts people in all nations and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.